{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:53Z","timestamp":1791478073892,"version":"4.3.4"},"reference-count":70,"publisher":"China Science Publishing & Media Ltd.","issue":"6","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.3724\/abbs.2026026","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:50:02Z","timestamp":1772506202000},"page":"1213-1222","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["The EBV-MS paradigm: beyond molecular mimicry toward                     new therapeutic strategies"],"prefix":"10.3724","volume":"58","author":[{"given":"Huating","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"Walton C","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N. Rising prevalence of multiple sclerosis worldwide: insights from                         the Atlas of MS, third edition. Mult Scler, 2020, 26: 1816-1821.","journal-title":"Mult Scler"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12883-018-1026-3","volume":"18","author":"Alroughani R","year":"2018","unstructured":"Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol, 2018, 18:","journal-title":"BMC Neurol"},{"key":"CITATION3","unstructured":"Rodgers MM, Mulcare JA, King DL, Mathews T, Gupta SC, Glaser RM.                         Gait characteristics of individuals with multiple sclerosis before and after                         a 6-month aerobic training program.                              J Rehabil Res Dev                          1999,                         36: 183\u2013188."},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","volume":"160","author":"Brodin P","year":"2015","unstructured":"Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJL, Furman D, Shen-Orr S. Variation in the human immune system is largely driven by                         non-heritable influences. Cell, 2015, 160: 37-47.","journal-title":"Cell"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","volume":"16","author":"Young LS","year":"2016","unstructured":"Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing                         surprises. Nat Rev Cancer, 2016, 16: 789-802.","journal-title":"Nat Rev Cancer"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"e2001992","DOI":"10.1371\/journal.pbio.2001992","volume":"15","author":"Styles CT","year":"2017","unstructured":"Styles CT, Bazot Q, Parker GA, White RE, Paschos K, Allday MJ, Sugden B. EBV epigenetically suppresses the B cell-to-plasma cell                         differentiation pathway while establishing long-term latency. PLoS Biol, 2017, 15:","journal-title":"PLoS Biol"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1126\/scitranslmed.3002878","volume":"3","author":"Cohen JI","year":"2011","unstructured":"Cohen JI, Fauci AS, Varmus H, Nabel GJ. Epstein-Barr virus: an important vaccine target for cancer                         prevention. Sci Transl                             Med, 2011, 3:","journal-title":"Sci Transl                             Med"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.20820","volume":"59","author":"Thacker EL","year":"2006","unstructured":"Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a                         meta-analysis. Ann Neurol, 2006, 59: 499-503.","journal-title":"Ann Neurol"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"Young LS","year":"2004","unstructured":"Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer, 2004, 4: 757-768.","journal-title":"Nat Rev Cancer"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41584-024-01167-9","volume":"20","author":"Robinson WH","year":"2024","unstructured":"Robinson WH, Younis S, Love ZZ, Steinman L, Lanz TV. Epstein-Barr virus as a potentiator of autoimmune diseases. Nat Rev                             Rheumatol, 2024, 20: 729-740.","journal-title":"Nat Rev                             Rheumatol"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"26318","DOI":"10.1073\/pnas.2007946117","volume":"117","author":"Fish K","year":"2020","unstructured":"Fish K, Comoglio F, Shaffer Iii AL, Ji Y, Pan KT, Scheich S, Oellerich A. Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A. Proc Natl Acad Sci                             USA, 2020, 117: 26318-26327.","journal-title":"Proc Natl Acad Sci                             USA"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1016\/j.cell.2024.06.021","volume":"187","author":"Huang J","year":"2024","unstructured":"Huang J, Zhang X, Nie X, Zhang X, Wang Y, Huang L, Geng X. Assembly and activation of EBV latent membrane protein 1. Cell, 2024, 187: 4996-5009.e14.","journal-title":"Cell"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.semcancer.2008.10.008","volume":"18","author":"Ressing ME","year":"2008","unstructured":"Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M. Epstein-Barr virus evasion of CD8+ and CD4+ T cell immunity via                         concerted actions of multiple gene products. Semin                             Cancer Biol, 2008, 18: 397-408.","journal-title":"Semin                             Cancer Biol"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","volume":"603","author":"Lanz TV","year":"2022","unstructured":"Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, Fernandes RA. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1                         and GlialCAM. Nature, 2022, 603: 321-327.","journal-title":"Nature"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"Bjornevik K","year":"2022","unstructured":"Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ. Longitudinal analysis reveals high prevalence of Epstein-Barr                         virus associated with multiple sclerosis. Science, 2022, 375: 296-301.","journal-title":"Science"},{"key":"CITATION16","unstructured":"Marie P. Scl\u00e9rose en plaques et maladies infectieuses.                              Gazette des H\u00f4pitaux                                                  1884, 57: 388\u2013389."},{"key":"CITATION17","doi-asserted-by":"crossref","unstructured":"TM R. Relation of filtrable viruses to diseases of the nervous                         system.                              Arch NeurPsych                          1932,                         757\u2013777.","DOI":"10.1001\/archneurpsyc.1932.02240040002001"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3181\/00379727-111-27855","volume":"111","author":"Adams JM","year":"1962","unstructured":"Adams JM, Imagawa DT. Measles antibodies in multiple sclerosis. Exp Biol Med, 1962, 111: 562-566.","journal-title":"Exp Biol Med"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/s0140-6736(81)91527-0","volume":"318","author":"Warner HB","year":"1981","unstructured":"Warner HB, Carp RI. Multiple sclerosis and Epstein-Barr virus. Lancet, 1981, 318:","journal-title":"Lancet"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1128\/CMR.6.4.382","volume":"6","author":"Kurtzke JF","year":"1993","unstructured":"Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev, 1993, 6: 382-427.","journal-title":"Clin Microbiol Rev"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","volume":"80","author":"Wucherpfennig KW","year":"1995","unstructured":"Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides                         activate human T cell clones specific for myelin basic protein. Cell, 1995, 80: 695-705.","journal-title":"Cell"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1084\/jem.20072397","volume":"205","author":"Lu\u0308nemann JD","year":"2008","unstructured":"Lu\u0308nemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R, Mu\u0308nz C. EBNA1-specific T cells from patients with multiple sclerosis                         cross react with myelin antigens and co-produce IFN-\u03b3 and IL-2. J Exp Med, 2008, 205: 1763-1773.","journal-title":"J Exp Med"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11481-010-9201-3","volume":"5","author":"Ascherio A","year":"2010","unstructured":"Ascherio A, Munger KL. Epstein-Barr virus infection and multiple sclerosis: a review. J Neuroimmune                             Pharmacol, 2010, 5: 271-277.","journal-title":"J Neuroimmune                             Pharmacol"},{"key":"CITATION24","doi-asserted-by":"crossref","unstructured":"Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA,                         Moutsianas L, Dilthey A, et al. Genetic risk and a primary                         role for cell-mediated immune mechanisms in multiple sclerosis.                              Nature                          2011, 476: 214\u2013219.","DOI":"10.1038\/nature10251"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"102332","DOI":"10.1016\/j.jaut.2019.102332","volume":"106","author":"Jog NR","year":"2020","unstructured":"Jog NR, McClain MT, Heinlen LD, Gross T, Towner R, Guthridge JM, Axtell RC. Epstein-Barr virus nuclear antigen 1 (EBNA-1) peptides recognized                         by adult multiple sclerosis patient sera induce neurologic symptoms in a                         murine model. J Autoimmunity, 2020, 106:","journal-title":"J Autoimmunity"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","volume":"50","author":"Harley JB","year":"2018","unstructured":"Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, Magnusen AF. Transcription factors operate across disease loci, with EBNA2                         implicated in autoimmunity. Nat Genet, 2018, 50: 699-707.","journal-title":"Nat Genet"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1084\/jem.20071030","volume":"204","author":"Serafini B","year":"2007","unstructured":"Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L. Dysregulated Epstein-Barr virus infection in the multiple                         sclerosis brain. J Exp Med, 2007, 204: 2899-2912.","journal-title":"J Exp Med"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1038\/cti.2016.87","volume":"6","author":"Pender MP","year":"2017","unstructured":"Pender MP, Csurhes PA, Burrows JM, Burrows SR. Defective T-cell control of Epstein-Barr virus infection in                         multiple sclerosis. Clin Trans Imm, 2017, 6:","journal-title":"Clin Trans Imm"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/0092-8674(91)90007-l","volume":"65","author":"Henderson S","year":"1991","unstructured":"Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E. Induction of Bcl-2 expression by Epstein-Barr virus latent                         membrane protein 1 protects infected B cells from programmed cell death. Cell, 1991, 65: 1107-1115.","journal-title":"Cell"},{"key":"CITATION30","doi-asserted-by":"crossref","unstructured":"Thorley-Lawson DA. EBV persistence\u2014introducing the virus.                              Curr Top Microbiol Immunol                                                  2015, 390: 151\u2013209.","DOI":"10.1007\/978-3-319-22822-8_8"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"Magliozzi R","year":"2006","unstructured":"Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R. Meningeal B-cell follicles in secondary progressive multiple                         sclerosis associate with early onset of disease and severe cortical                         pathology. Brain, 2006, 130: 1089-1104.","journal-title":"Brain"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s12276-025-01482-5","volume":"57","author":"Nguyen HD","year":"2025","unstructured":"Nguyen HD, Kim D, Kim YH, Flemington E, Giovannoni G, Park CG, Kim WK. Epstein-Barr virus and multiple sclerosis: lesson learned to                         develop better nonhuman primate models. Exp Mol Med, 2025, 57: 1143-1151.","journal-title":"Exp Mol Med"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"578314","DOI":"10.1016\/j.jneuroim.2024.578314","volume":"389","author":"Serafini B","year":"2024","unstructured":"Serafini B, Benincasa L, Rosicarelli B, Aloisi F. EBV infected cells in the multiple sclerosis brain express PD-L1:                         how the virus and its niche may escape immune surveillance. J                             Neuroimmunol, 2024, 389:","journal-title":"J                             Neuroimmunol"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awl067","volume":"129","author":"Lunemann JD","year":"2006","unstructured":"Lunemann JD. Increased frequency and broadened specificity of latent EBV                         nuclear antigen-1-specific T cells in multiple sclerosis. Brain, 2006, 129: 1493-1506.","journal-title":"Brain"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"e1003220","DOI":"10.1371\/journal.ppat.1003220","volume":"9","author":"Angelini DF","year":"2013","unstructured":"Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S. Increased CD8+ T cell response to Epstein-Barr virus lytic                         antigens in the active phase of multiple sclerosis. PLoS Pathog, 2013, 9:","journal-title":"PLoS Pathog"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJM200008173430707","volume":"343","author":"Cohen JI","year":"2000","unstructured":"Cohen JI. Epstein-Barr virus infection. N Engl J Med, 2000, 343: 481-492.","journal-title":"N Engl J Med"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1474-4422(24)00027-9","volume":"23","author":"Chataway J","year":"2024","unstructured":"Chataway J, Williams T, Li V, Marrie RA, Ontaneda D, Fox RJ. Clinical trials for progressive multiple sclerosis: progress, new                         lessons learned, and remaining challenges. Lancet                             Neurol, 2024, 23: 277-301.","journal-title":"Lancet                             Neurol"},{"key":"CITATION38","unstructured":"Klotz L, Saraste M, Airas L, Kuhlmann T. Multiple sclerosis: 2024                         update.                              Free Neuropathol                          2025, 6:                         14."},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00401-022-02411-w","volume":"143","author":"Li R","year":"2022","unstructured":"Li R, Tang H, Burns JC, Hopkins BT, Le Coz C, Zhang B, de Barcelos IP. BTK inhibition limits B-cell-T-cell interaction through                         modulation of B-cell metabolism: implications for multiple sclerosis therapy. Acta                             Neuropathol, 2022, 143: 505-521.","journal-title":"Acta                             Neuropathol"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"102012","DOI":"10.1016\/j.disamonth.2025.102012","volume":"71","author":"Prajjwal P","year":"2025","unstructured":"Prajjwal P, Patel PV, Patel ZV, Inban P, Patel D, Mahato P, Shamim L. Multiple sclerosis updates and the safety and efficacy of Bruton                         tyrosine kinase inhibitors in it: a systematic review. Dis Mon, 2025, 71:","journal-title":"Dis Mon"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","volume":"23","author":"Montalban X","year":"2024","unstructured":"Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E. Safety and efficacy of evobrutinib in relapsing multiple                         sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised,                         double-blind, active-controlled, phase 3 trials. Lancet                             Neurol, 2024, 23: 1119-1132.","journal-title":"Lancet                             Neurol"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"Hauser SL","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F. Ocrelizumab versus interferon beta-1a in relapsing multiple                         sclerosis. N Engl J Med, 2017, 376: 221-234.","journal-title":"N Engl J Med"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/jci.insight.126599","volume":"4","author":"Greenfield AL","year":"2019","unstructured":"Greenfield AL, Dandekar R, Ramesh A, Eggers EL, Wu H, Laurent S, Harkin W. Longitudinally persistent cerebrospinal fluid B-cells can resist                         treatment in multiple sclerosis. JCI Insight, 2019, 4:","journal-title":"JCI Insight"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/brain\/awh680","volume":"129","author":"Krumbholz M","year":"2006","unstructured":"Krumbholz M, Theil D, Cepok S, Hemmer B, Kivis\u00e4kk P, Ransohoff RM, Hofbauer M. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation                         is differentially linked to CNS immune cell recruitment. Brain, 2006, 129: 200-211.","journal-title":"Brain"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0b013e3181c5b457","volume":"73","author":"Sellebjerg F","year":"2009","unstructured":"Sellebjerg F, Bo\u0308rnsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, S\u00f8rensen PS. Increased cerebrospinal fluid concentrations of the chemokine                         CXCL13 in active MS. Neurology, 2009, 73: 2003-2010.","journal-title":"Neurology"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"M\u00fcller F","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, Aigner M. CD19 CAR T-Cell therapy in autoimmune disease\u2014a case series with                         follow-up. N Engl J Med, 2024, 390: 687-700.","journal-title":"N Engl J Med"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"652811","DOI":"10.3389\/fneur.2021.652811","volume":"12","author":"Ioannides ZA","year":"2021","unstructured":"Ioannides ZA, Csurhes PA, Douglas NL, Mackenroth G, Swayne A, Thompson KM, Hopkins TJ. Sustained clinical improvement in a subset of patients with                         progressive multiple sclerosis treated with epstein\u2013barr virus-specific t                         cell therapy. Front Neurol, 2021, 12:","journal-title":"Front Neurol"},{"key":"CITATION48","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.tips.2025.05.001","volume":"46","author":"Lewash M","year":"2025","unstructured":"Lewash M, Kostenis E, M\u00fcller CE. GPR17-orphan G protein-coupled receptor with therapeutic                         potential. Trends                             Pharmacol Sci, 2025, 46: 610-628.","journal-title":"Trends                             Pharmacol Sci"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/pathogens11101095","volume":"11","author":"Zhou J","year":"2022","unstructured":"Zhou J, Chen J, Peng Y, Xie Y, Xiao Y. A promising tool in serological diagnosis: current research                         progress of antigenic epitopes in infectious diseases. Pathogens, 2022, 11:","journal-title":"Pathogens"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41586-025-09188-4","volume":"644","author":"Dai Y","year":"2025","unstructured":"Dai Y, Aizenbud L, Qin K, Austin M, Jaycox JR, Cunningham J, Wang EY. Humoral determinants of checkpoint immunotherapy. Nature, 2025, 644: 527-536.","journal-title":"Nature"},{"key":"CITATION51","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s11481-020-09948-1","volume":"16","author":"Wang Z","year":"2021","unstructured":"Wang Z, Kennedy PG, Dupree C, Wang M, Lee C, Pointon T, Langford TD. Antibodies from multiple sclerosis brain identified Epstein-Barr                         virus nuclear antigen 1 & 2 epitopes which are recognized by oligoclonal                         bands. J Neuroimmune                             Pharmacol, 2021, 16: 567-580.","journal-title":"J Neuroimmune                             Pharmacol"},{"key":"CITATION52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nbt.1856","volume":"29","author":"Larman HB","year":"2011","unstructured":"Larman HB, Zhao Z, Laserson U, Li MZ, Ciccia A, Gakidis MAM, Church GM. Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol, 2011, 29: 535-541.","journal-title":"Nat Biotechnol"},{"key":"CITATION53","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41591-024-02938-3","volume":"30","author":"Zamecnik CR","year":"2024","unstructured":"Zamecnik CR, Sowa GM, Abdelhak A, Dandekar R, Bair RD, Wade KJ, Bartley CM. An autoantibody signature predictive for multiple sclerosis. Nat Med, 2024, 30: 1300-1308.","journal-title":"Nat Med"},{"key":"CITATION54","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s41591-021-01409-3","volume":"27","author":"Vogl T","year":"2021","unstructured":"Vogl T, Klompus S, Leviatan S, Kalka IN, Weinberger A, Wijmenga C, Fu J. Population-wide diversity and stability of serum antibody epitope                         repertoires against human microbiota. Nat Med, 2021, 27: 1442-1450.","journal-title":"Nat Med"},{"key":"CITATION55","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.immuni.2023.04.003","volume":"56","author":"Andreu-S\u00e1nchez S","year":"2023","unstructured":"Andreu-S\u00e1nchez S, Bourgonje AR, Vogl T, Kurilshikov A, Leviatan S, Ruiz-Moreno AJ, Hu S. Phage display sequencing reveals that genetic, environmental, and                         intrinsic factors influence variation of human antibody epitope repertoire. Immunity, 2023, 56: 1376-1392.e8.","journal-title":"Immunity"},{"key":"CITATION56","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41586-024-07722-4","volume":"632","author":"Bodansky A","year":"2024","unstructured":"Bodansky A, Mettelman RC, Sabatino Jr JJ, Vazquez SE, Chou J, Novak T, Moffitt KL. Molecular mimicry in multisystem inflammatory syndrome in                         children. Nature, 2024, 632: 622-629.","journal-title":"Nature"},{"key":"CITATION57","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13075-015-0685-3","volume":"17","author":"Araujo GR","year":"2015","unstructured":"Araujo GR, Vaz ER, Fujimura PT, Fonseca JE, de Lima LM, Canh\u00e3o H, Venturini G. Improved serological detection of rheumatoid arthritis: a highly                         antigenic mimotope of carbonic anhydrase III selected in a murine model by                         phage display. Arthritis Res                             Ther, 2015, 17:","journal-title":"Arthritis Res                             Ther"},{"key":"CITATION58","doi-asserted-by":"publisher","first-page":"e78550","DOI":"10.7554\/eLife.78550","volume":"11","author":"Vazquez SE","year":"2022","unstructured":"Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferr\u00e9 EM, Landegren N. Autoantibody discovery across monogenic, acquired, and                         COVID-19-associated autoimmunity with scalable PhIP-seq. eLife, 2022, 11:","journal-title":"eLife"},{"key":"CITATION59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1084\/jem.188.1.29","volume":"188","author":"Putterman C","year":"1998","unstructured":"Putterman C, Diamond B. Immunization with a peptide surrogate for double-stranded DNA                         (dsDNA) induces autoantibody production and renal immunoglobulin deposition. J Exp Med, 1998, 188: 29-38.","journal-title":"J Exp Med"},{"key":"CITATION60","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2337\/dc09-0449","volume":"32","author":"Walter M","year":"2009","unstructured":"Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R. No effect of the altered peptide ligand NBI-6024 on \u03b2-cell                         residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care, 2009, 32: 2036-2040.","journal-title":"Diabetes Care"},{"key":"CITATION61","doi-asserted-by":"crossref","unstructured":"Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, et                         al. Diverse functional autoantibodies in patients with COVID-19.                              Nature                          2021, 595: 283\u2013288.","DOI":"10.1038\/s41586-021-03631-y"},{"key":"CITATION62","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2337\/db13-0619","volume":"63","author":"Laitinen OH","year":"2014","unstructured":"Laitinen OH, Honkanen H, Pakkanen O, Oikarinen S, Hankaniemi MM, Huhtala H, Ruokoranta T. Coxsackievirus B1 is associated with induction of \u03b2-cell                         autoimmunity that portends type 1 diabetes. Diabetes, 2014, 63: 446-455.","journal-title":"Diabetes"},{"key":"CITATION63","doi-asserted-by":"publisher","first-page":"6460","DOI":"10.1126\/science.aav7188","volume":"365","author":"Patsopoulos NA","year":"2019","unstructured":"Patsopoulos NA, Baranzini SE, Santaniello A, Shoostari P, Cotsapas C, Wong G, Beecham AH. Multiple sclerosis genomic map implicates peripheral immune cells                         and microglia in susceptibility. Science, 2019, 365:","journal-title":"Science"},{"key":"CITATION64","doi-asserted-by":"publisher","first-page":"aaa0698","DOI":"10.1126\/science.aaa0698","volume":"348","author":"Xu GJ","year":"2015","unstructured":"Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndung\u2019u T, Ruxrungtham K. Comprehensive serological profiling of human populations using a                         synthetic human virome. Science, 2015, 348:","journal-title":"Science"},{"key":"CITATION65","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","volume":"296","author":"Munger KL","year":"2006","unstructured":"Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA, 2006, 296:","journal-title":"JAMA"},{"key":"CITATION66","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.cell.2022.08.021","volume":"185","author":"Zhou X","year":"2022","unstructured":"Zhou X, Baumann R, Gao X, Mendoza M, Singh S, Katz Sand I, Xia Z. Gut microbiome of multiple sclerosis patients and paired                         household healthy controls reveal associations with disease risk and course. Cell, 2022, 185: 3467-3486.e16.","journal-title":"Cell"},{"key":"CITATION67","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/fmb.10.123","volume":"5","author":"Kakalacheva K","year":"2010","unstructured":"Kakalacheva K, Comabella M. Epstein-Barr virus and multiple sclerosis: causation or                         association?. Future Microbiol, 2010, 5: 1617-1619.","journal-title":"Future Microbiol"},{"key":"CITATION68","doi-asserted-by":"publisher","first-page":"108072","DOI":"10.1016\/j.jbc.2024.108072","volume":"301","author":"Keen MM","year":"2025","unstructured":"Keen MM, Keith AD, Ortlund EA. Epitope mapping via in vitro deep mutational                         scanning methods and its applications. J Biol Chem, 2025, 301:","journal-title":"J Biol Chem"},{"key":"CITATION69","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","volume":"9","author":"Song Y","year":"2024","unstructured":"Song Y, Li J, Wu Y. Evolving understanding of autoimmune mechanisms and new                         therapeutic strategies of autoimmune disorders. Sig Transduct                             Target Ther, 2024, 9:","journal-title":"Sig Transduct                             Target Ther"},{"key":"CITATION70","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12967-022-03328-4","volume":"20","author":"Rojas M","year":"2022","unstructured":"Rojas M, Rodr\u00edguez Y, Acosta-Ampudia Y, Monsalve DM, Zhu C, Li QZ, Ram\u00edrez-Santana C. Autoimmunity is a hallmark of post-COVID syndrome. J Transl Med, 2022, 20:","journal-title":"J Transl Med"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/0541B5475A1745038C9B8F2B0F0EC191","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026026","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/0541B5475A1745038C9B8F2B0F0EC191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:12:57Z","timestamp":1781773977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,3]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2026026","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}